$OVID News

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey Rona

Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally

Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate

Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks

Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders - Slideshow

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

Ovid Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $2 to $4.